Glofitamab induces CR in patients with r/r DLBCL

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

B-cell acute lymphoblastic leukemia is a common type of ALL in adults.

March 07, 2025

FDA accepts review for odronextamab BLA in r/r follicular lymphoma

FDA accepted for review the resubmission of the Regeneron Pharmaceuticals, Inc.’s Biologics License Application for Ordspono (odronextamab) in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. The target action date for the FDA decision is July 30.

February 28, 2025

Vol.51 No.08

Drugs & Targets

FDA clears IND application for LTZ-301

FDA cleared the LTZ Therapeutics’s Investigational New Drug application for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma.

February 28, 2025

Vol.51 No.08

Clinical Roundup

CAR T therapy shows durable responses in large B-cell lymphoma

Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.

February 21, 2025

Vol.51 No.07

Drugs & Targets

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.

February 14, 2025

Vol.51 No.06

Clinical Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).

February 07, 2025

Vol.51 No.05

By Lee Greenberger